GNE-9815 - 10mM in DMSO , CAS No.2729996-45-4

CAS: 2729996-45-4 Cat. No.: G654584 Summenformel: C₂₆H₂₂FN₅O₂ Molekulargewicht: 455.48

GRADE & PURITY 10mM in DMSO

Storage

Store at -80°C

Shipped In

Dry ice packs + Cold packs

Übersicht

GNE-9815 (compound 7) is a highly selective, pan- RAF inhibitor with good oral bioavailability. GNE-9815 exhibits K i values of 0.062 and 0.19 nM for CRAF and BRAF , respectively. GNE-9815 combines with MEK inhibitor Cobimetinib shows synergistic modulation of MAPK pathway. GNE-9815 can be used in studies of KRAS mutant cancers

In Vitro

GNE-9815 shows synergistic activity in KRAS mutant A549 and HCT116 cancer cells in combination with the MEK inhibitor Cobimetinib. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

GNE-9815 (15 mg/kg; p.o.; single) demonstrates synergistic MAPK pathway modulation when combines with the MEK inhibitor Cobimetinib in an HCT116 xenograft mouse model . GNE-9815 (5 mg/kg; p.o.; single) shows good oral bioavailability and (1 mg/kg; i.v.; single) exhibits low blood clearance, moderate volume of distribution, and short half-life . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Female NCR nude mice (6 to 8-week-old; 24-26 g; HCT116 xenograft mice model) . Dosage: 15 mg/kg Administration: Intravenous injection or oral administration; single. Result: Resulted in pathway inhibition as demonstrated by partial inhibition of pRSK between 2 and 24 h, but more robust, albeit transient, inhibition of the downstream MAPK target genes, DUSP6 and SPRY4. Led to deeper inhibition of the downstream MAPK target genes DUSP6 and SPRY4, when combined with the MEK inhibitor Cobimetinib, with maximal inhibition at 8 h and with a more modest rebound in levels at 24 h, post final dose. Animal Model: Female NCR nude mice (6 to 8-week-old; 24-26 g) . Dosage: 1 mg/kg (for i.v.); 5 mg/kg (for p.o.). Administration: Intravenous injection or oral administration; single. Result: Exhibited CL b , V dss and t 1/2 values of 17 mL/min∙kg, 1.7 L/kg and 1.9 h, respectively. Showed good oral bioavailability with F% of 37%. (methylcellulose/Tween formulation).

IC50& Target:CRAF 0.062 nM (Ki) Braf 0.19 nM (Ki)

Specifications

Spezifikationen & Reinheit

10mM in DMSO

Biochemische und physiologische Mechanismen

GNE-9815 (compound 7) is a highly selective, pan- RAF inhibitor with good oral bioavailability. GNE-9815 exhibits K i values of 0.062 and 0.19 nM for CRAF and BRAF , respectively. GNE-9815 combines with MEK inhibitor Cobimetinib ( HY-13064 ) shows synergi

Storage

Store at -80°C

Verschickt in

Dry ice packs + Cold packs

Dieses Produkt erfordert Kühlkettenversand. Grundversand und andere Economy-Optionen sind nicht verfügbar.

Aktionsart

INHIBITOR

Namen und Kennungen

• Molekulargewicht: 455.48

Häufig gestellte Fragen

How should this product be stored?

Store at ?80 °C. Ultra-low temperature storage is required to maintain the specified shelf life.

How is this product shipped?

This product ships frozen with dry ice and cold packs. Unpack on arrival and transfer it to the storage condition stated above; handle dry ice with insulated gloves in a ventilated area.

What are the CAS number, molecular formula and molecular weight?

The CAS Number is 2729996-45-4, the molecular formula is C26H22FN5O2, and the molecular weight is 455.48 g/mol.

What documentation is provided?

Available product documentation, including Certificates of Analysis (COA), Safety Data Sheets (SDS), and specification sheets, is shown in the product document area. Document availability and access follow the current site policy.